膦甲酸钠联合阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床研究

Objective To investigate the efficacy and safety of foscarnet sodium combined with adefovir dipivoxil for Chinese chronic hipatitis B patients with lamivudine resistance.Methods 70 chronic hepatitis B patients with lamivudine resistanc were ramdomly put in a foscarnet sodium combined with adefovir dipivoxil group (36 patients) or an adefovir dipivoxil group (34 patients) .After 4 and 12-weeks of treatment, serum HBV DNA levels were measured by quantitative PCR and liver function tests.Results In the foscarnet sodium combined with adefovir dipivoxil group, the virological response and the liver function normalization at 4 and 12 weeks were significantly higher than those in the the adefovir dipivoxil group.There was no adverse event related to the investigational product in this trial.There was no significant difference between the two groups in the incidence of adverse events.Conclusion It was shown that foscarnet sodium combined with adefovir dipivoxil were effective and safe for the treatment of chronic hepatitis B patients with lamivudine resistance.